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Abstract
The prevention of hepatitis B is important, since it is responsible for significant morbidity and mortality around the world. Unfortunately,
hepatitis B vaccine does not always induce protective immunity. The lack of immune response to vaccine (non-responders) can depend on
individual characteristics.
The objective of this study was to correlate the CD26/DPPIV cellular expression and DPPIV serum activity with HBV vaccine response
and its possible role as an indicator of immune competence acquisition. We also determined the cellular expression of CD3, CD19, CD56 and
CD25 in peripheral blood T lymphocytes.
Blood samples were obtained from 28 healthy human volunteers who were enrolled with a vaccination program. There were “responders”
(RM = 13) and “non-responders” (NRM = 15), after vaccination. The lymphocyte populations were identified by flow cytometry. DPPIV
serum activity was measured fluorimetrically.
CD26 expression in responders (55.9 ± 7.7%) versus in non-responders (51.9 ± 7.0%) did not show a significant difference. The DPPIV
serum activity in responders compared to in non-responder subgroup (59.9± 8.4/50.3± 10.6 U/L) showed, however, a significant difference
(P < 0.05). The expression of CD3, CD19 and CD56 on peripheral lymphocytes was similar between responders and non-responders. The
expression of CD3CD26 (52.2 ± 8.6%) and CD3CD25 (10.9 ± 3.8%) in responders versus the expression of CD3CD26 (48.0 ± 5.7%) and
CD3CD25 (8 ± 4.6%) in non-responders did not show statistically significant difference.
CD25 referred as a marker of T lymphocyte activation was increased in responders (15.8± 4.5%) versus in non-responders (10.1± 4.8%),
showing a significant difference (P = 0.003). It was, however, impossible to demonstrate an increase in CD3CD25 and CD3CD26 in the
responder subgroup. This suggests that different lymphocyte subsets other than T cells are implicated in the response to hepatitis B vaccination.
© 2004 Published by Elsevier Ireland Ltd.
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1. Introduction
Hepatitis B is one of the most important infectious dis-
eases around the world. Its importance is due to the enor-
mous number of infected persons, about two billion. It is also
due to its subsequent complications such as fulminant and
fatal acute hepatitis, chronic liver disease with cirrhosis and
even hepatocellular carcinoma. The chronic carriers consti-
tute the main human reservoir of hepatitis B [1,2]. Groups
with high rates of hepatitis B virus (HBV) infection include
also healthcare workers daily exposed to blood and other
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body fluids. In these particularly exposed groups, vaccina-
tion programs are indicated, since the hospital-wide hepati-
tis B immunisation programme helps to raise the immune
status of the staff, and to reduce the costs of prophylactic
usage of hepatitis B immunoglobulin.
The recombinant hepatitis B virus vaccine has been used
for more than a decade. It consists in non-glycosylated
HbsAg particles, but it is otherwise indistinguishable from
natural HbsAg. It is comparable, in immunogenecity, protec-
tive efficacy and safety to the first generation plasma-derived
vaccine [1,3].
Unfortunately, 2–10% of healthy and immunocompe-
tent adults do not respond to vaccination with the pro-
duction of protective levels of anti-HBS antibody. This
fact could be related to a diversity of factors such as:
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sex, age, genetic factors, and some environmental factors
[4].
Nevertheless, as hepatitis B is a preventable disease by
immunization, the most efficient way to prevent it, is a vac-
cination program. It is agreed that a universal hepatitis B
vaccination should be encouraged in order to reduce the
morbidity and the mortality attributable to liver disease and
its complications [5,6].
Traditionally HBV vaccination response markers have
been the anti-Hbs antibodies serum titters (>100 U/L, re-
sponders; <10 U/L, non-responders). The knowledge of the
mechanisms by which the immune response can be induced
is important, and so is the knowledge of new peripheral
blood cell markers, which should give an overview of the
immune system pathways.
Dipeptidyl peptidase IV (DPPIV), a membrane bound ex-
opeptidase, has been identified as the surface antigen CD26.
Like several other surface enzymes, CD26/DPPIV is ex-
pressed on a variety of tissues and cell types, including the
T cells, in particular in memory T lymphocytes, as well as
on the endothelial and epithelial cells [7].
CD26/DPPIV is a multifunctional molecule that interferes
with many immune functions, both in vitro and in vivo. In
addition to its membrane-associated form, CD26/DPPIV is
also present as a soluble exopeptidase in various body fluids,
such as plasma, serum and urine [8–21].
DPPIV has an unique aminopeptidase activity. It cleaves
dipeptides from the NH2-terminus of proteins, having a pro-
line, a hydroxiproline or an alanine residue at the penul-
timate position, with the highest efficiency observed with
proline residues [13,19,22–25].
Independently of its peptidase activity, CD26/DPPIV is
associated to other molecules on the cell surface. For in-
stance, on T lymphocytes, it is associated with CD45, a
cell surface expressed phosphotyrosine phosphatase, which
is involved in signal transduction. It has been shown to
be the main receptor of adenosine deaminase of the T-cell
surface, thus protecting the cell from adenosine mediated
inhibition of proliferation. In addition, it has also been pro-
posed that CD26 is involved in the pathophysiology of the
acquired immune deficiency syndrome (AIDS). It is clear
that CD26/DPPIV is involved in multiple functional activi-
ties related with immune response. [10–12,14,15,22,26–37].
Both features of CD26/DPPIV, as a membrane antigen
and as a peptidase, contribute to the co-stimulation of CD26
in T-cell activation events. The role of CD26/DPPIV in these
events is, however, unclear [10,14,38–40].
In view of the established relevance of CD26/DPPIV as a
T-cell activation marker our aim was to clarify whether its
expression on T cells would change after hepatitis B vac-
cination and, according to the vaccination response, what
differences are observed [8]. Therefore, we studied the ex-
pression of CD26 in the peripheral blood T lymphocytes
and serum DPPIV activity. The main lymphocyte popula-
tions (CD3, CD19 and CD56), were also studied for com-
parison to see the expression rate of CD26 in T lymphocytes
(CD3) and also of CD25, a known marker of T lymphocyte
activation.
2. Materials and methods
2.1. Subjects and blood sampling
Healthy volunteer healthcare workers (M = 28) at the
University Hospital of Coimbra (HUC) who were enrolled in
an anti-HBV vaccination program, proposed by the medical
service of the hospital, participated in this study.
After the vaccination program, individuals were grouped
as: “responders” (R), anti-Hbs >100 UI/L (n = 13) and
“non-responders” (NR), anti-Hbs <10 UI/L (n = 15).
Peripheral blood samples (10 mL) were obtained by ve-
nous puncture. The samples were divided in two aliquots:
4 mL were collected with EDTA to perform flow cytometry
analysis; 6 mL was collected without anticoagulant and al-
lowed to clot at room temperature, centrifuged at 2000× g,
for 15 min, and the serum was removed and stored at−30 ◦C,
until assayed.
2.2. Flow cytometry
We used monoclonal antibodies that were directly
conjugated to one of the following fluorochromes: flu-
orescein isothiocyanate (FICT), phycoerythrin (PE), or
phycoerythrin–cyanin 5.1 (PECy5).
Lymphocyte subsets were studied by two and three colour
immunofluorescences with conjugated monoclonal antibod-
ies: anti-CD3 from Dako® (PECy5); anti-CD19 (Fitc) and
anti-CD56 (PE) from Immunotech®, anti-CD26 (PE) and
anti-CD25 (PE) from Immune Source®. Residual red blood
cells were lysed with “Lysing Solution®” from Becton
Dickinson®. Cells were resuspended in phosphate-buffered
saline (PBS) until analysis.
Flow cytometry was performed using a FacsCaliburTM
from Becton Dickinson, collecting 10,000 events by acqui-
sition. The lymphocyte population was identified by light
scattering and fluorescent properties, gated and analysed.
2.3. Serum DPPIV activity was measured by a fluorimetric
assay previously described by Sharpé et al. [41]
DPPIV was recorded by the cleavage of the fluoro-
genic substrate Gly-Pro-4-Me-2-NA, Sigma–Aldrich Co.
(St. Louis, 63178 Missouri, USA) releasing a highly fluo-
rescent molecule: 4-Me-2-NA. For the substrate solution,
20 mmol/L, substrate was dissolved in 1 mL of DMSO. This
solution was stored at 4 ◦C.
Standard solution, 4-Me-2-NA was acquired from
Bachem Feinchemikalien AG, (Budendorf, Switzerland).
The stock solution was 50 mmol/L 4-Me-2-NA in DMSO.
Before use it was dissolved as required with stopping solu-
tion.
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Incubation buffer was a 50 mmol/L Tris–HCl solution, pH
8.3, adjusted at room temperature, stored at 4 ◦C. Stopping
solution was a 100 mmol/L citrate solution, pH 4.0, adjusted
at room temperature and stored at the refrigerator at 4 ◦C.
The fluorescence was measured with a JASCO FP-777 spec-
trofluorimeter, with a quartz cell, at 340 nm of excitation and
at 425 nm of the emission wavelengths.
Serum DPPIV activity has been expressed in units/litre
(U/L). One unit (U) of DPPIV activity was defined as the en-
zyme activity that produced 1mol of 4-Me-2-NA in 1 min
under the reaction conditions.
2.4. Statistical analysis
Student’s t-test was used to determine the statistical sig-
nificance, considering a P-value of <0.05 being significant.
3. Results
CD26 expression in responders (55.9 ± 7.7%) versus in
non-responders to hepatitis B vaccine (51.9 ± 7.0%) did not
show a significant difference (Table 1, Fig. 1).
In the two studied subgroups, serum DPPIV activity was
higher in R subgroup (59.9 ± 8.4 U/L) when compared to
the enzyme activity in NR subgroup (50.3 ± 10.6 U/L) with
a statistical significance (P < 0.05) (Table 2, Fig. 2).
Table 1
Monoclonal antibody markers—CD3, CD19, CD56, CD25, CD26,
CD3CD26 and CD3CD25—in hepatitis B virus vaccinated,
“non-responders” and “responders”
Non-responders (n = 15) Responders (n = 13)
CD3 (%) 79.6 ± 4.8 79.0 ± 7.7
CD19 (%) 9.6 ± 3.1 10.3 ± 3.8
CD56 (%) 10.7 ± 3.8 10.7 ± 4.8
CD25∗ (%) 10.1 ± 4.8 15.8 ± 4.5
CD26 (%) 51.9 ± 7.0 55.9 ± 7.7
CD3CD25 (%) 7.9 ± 4.6 10.9 ± 3.8
CD3CD26 (%) 49.0 ± 6.8 52.2 ± 8.6
CD3negCD26 (%) 2.8 ± 1.8 3.8 ± 1.6
Results are expressed in percentage of cells. CD26 is mainly expressed
by CD3 T lymphocytes, since CD3neg cells only expressed ±2.8% of
total CD26.
∗ P = 0.003.
Table 2
Protease DPPIV activity (U/L) in hepatitis B virus vaccinated group of
healthcare workers grouped, according to the vaccination response, in
“non-responders” and “responders”
DPPIV (U/L)
Non-responders (n = 15) 50.3 ± 10.6
Responders (n = 13) 59.8 ± 8.4
The “responders” showed a higher, and statistically significant, DPPIV
activity compared with “non-responders” DPPIV activity. Student’s t-test:
∗P < 0.05.
The CD3, CD19 and CD56 expression in T lympho-
cytes was similar take in R and NR subgroups. The ex-
pression of CD3CD26 (52.2 ± 8.6%) and CD3CD25 (10.9
± 3.8%) in responders versus (48.0 ± 5.7%) and (8 ±
4.6%), respectively, in non-responders, was not statistically
significant.
In responders, the expression of CD25 (15.8 ± 4.5%)
demonstrated a higher and significant difference when com-
pared with non-responders (10.1 ± 4.8%) (P = 0.003).
4. Discussion
The vaccination is the most important way to protect the
population against hepatitis B, since all are vulnerable due
to its infectivity and its complications such as acute and
fulminating hepatitis, cirrhosis and hepatocellular carcinoma
[2,42].
Healthcare workers are daily in exposure risk to infected
body fluids. That makes adequate hepatitis B immunisation
of healthcare workers a priority.
The effectiveness of hepatitis B vaccines is well known.
As previously mentioned traditionally serum titters of anti-
bodies are classical markers of protective immunity to HBV
infection. Unfortunately, a number of apparently healthy
and immunocompetent adults (2–10%) are unable to achieve
protective concentration of antibodies (>100 U/L) after vac-
cination. This suggests a defect in either B- or T-cell func-
tions in non-responder individuals [43,44]. Nevertheless,
antibody concentration only demonstrates a small part of the
complexity of immune response, without any information
about immune efficacy. The lack of response to hepatitis B
vaccination remains a problem for those individuals who are
directly in risk of hepatitis B infection.
When activated, T- and B-lymphocytes express a number
of surface molecules that are absent or present in low con-
centrations in resting lymphocytes. Among these molecules
are enzymes such as proteases like DPPIV, E.C.3.4.14.5 also
known as CD26. It has become a subject of specific interest
since it appears to have additional functions in T-cell acti-
vation as a co-stimulator molecule [14,39,45,46]. The pres-
ence of DPPIV in serum varies widely between individuals,
and it is increased upon cell activation. Previous studies have
shown roles for CD26 in T-cell activation. It is speculated
that CD26/DPPIV is potentially important in the achieve-
ment of immunocompetence [7,47,48].
DPPIV cleaves several cytokines, which could change the
characters of the local inflammatory response, affecting the
differentiation of responding lymphocytes into helper, cy-
totoxic and regulatory cell populations [7]. The mechanism
through which DPPIV influence T-cell functions has not,
however, been completely established [49].
The increase of CD26 expression in T-lymphocyte
and macrophage membranes has been linked to cell ac-
tivation and development of immunological memory
[49–51].
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Fig. 1. CD26 expression in peripheral blood T lymphocytes, on responders and non-responders. Data in percentage of cells that expressed CD26 surface
antigen.
The molecular mechanisms by which CD26 mediates the
T-cell stimulation/activation mechanisms appear to be asso-
ciated to the T-cell receptor (TCR), according to some au-
thors, but the role of this molecule in the regulation of the
immune response is only partly established [45,52].
According to other authors, the level of DPPIV activity is
not directly related to the intensity of CD26 expression on
the T cells [4,46]. Findings of others have led to the proposal
that DPPIV/CD26 may be involved in the switching of the
innate and acquired immune response [53].
Our present results showed that DPPIV serum activity
was significantly increased in the responders after vaccina-
tion. In our opinion, these DPPIV increased serum levels
may be related to successful activation of immune system
and to the acquisition of immune efficiency. Other workers
have published a significant decrease in T-cell proliferation,
cytokine levels and antibody production under the influence
of DPPIV specific inhibitors [14,54].
Fig. 2. Representation of DPPIV activity (U/L) in responders and
non-responders hepatitis B virus, after vaccination.
The expression of CD26 on the peripheral blood T lym-
phocytes did not show a significant difference between the
R and NR subgroups. The CD26 expression on CD3 lym-
phocytes, could be related to cells other than T lymphocytes,
and the present result may be due to insufficient sample size.
The increased significant DPPIV activity and the referred
modification of CD26 expression, in the responder subgroup,
might reflect an improvement in the individual immune sta-
tus after vaccination. This is emphasised by the significant
increase of CD25 (a classical marker of T lymphocyte activa-
tion) expression on R subgroup. This could render a greater
capacity to react against infection.
It remains to be proved that antibody concentration is the
best immunity marker of immune competence after hepatitis
B vaccination as the immunological memory, among many
others, are involved in the protection of vaccinated organ-
isms.
Further studies, involving larger sample sizes and addi-
tional complementary markers of immune protection will
probably answer some of the remaining questions that con-
tinue to challenge our knowledge of CD26/DPPIV interven-
tion in HBV immunisation.
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